Trial Profile
A Phase IIa, Randomized, Double-blind, Placebo-controlled, Exploratory, Dose-ranging Study to Evaluate the Safety, Effectiveness and Pharmacokinetics of Three Courses of DC-TAB Treatment in Patients With Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Alpha crystallin B (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Delta Crystallon
- 25 May 2015 New trial record